key: cord-0981529-pvrv0tel
authors: Nayak, Keshav R.; Maves, Ryan C.; Henry, Timothy
title: Management principles for the cardiac catheterization laboratory during the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic
date: 2022-03-28
journal: Interv Cardiol Clin
DOI: 10.1016/j.iccl.2022.03.005
sha: 8e4b7c6a3749d267955a16cb783f9501d8dd5bf6
doc_id: 981529
cord_uid: pvrv0tel

nan

1. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly contagious pathogen. The resulting illness, 2019 coronavirus disease (COVID- 19) , has significant morbidity and mortality and has a direct impact on cardiac catheterization laboratory (CCL) operations. The CCL needs formal preparedness protocols for safe, effective, and timely operations. There is a dire need for consensus evidence-based guidance and guidelines from international heart associations.

2.CCL teams are frontline workers, similar to emergency room and critical care teams. They directly care for patients with cardiovascular emergencies, including but not limited to ST-segment elevation MI (STEMI), in suspected or confirmed infected patients. 3 . Infection control principles center on three levels of hierarchical controls: (a) protection of the healthcare worker with personal protective equipment (PPE), (b) administrative (staff training, restriction of non-essential personnel with an optimized staffing matrix), and (c) environmental/engineering controls (social distancing, isolation of personnel from the infectious hazard). 4 . All CCL staff in direct contact with potentially infectious patients should be provided with N95 respirators, whole face shields or protective eyewear, disposable caps, shoe covers, sterile gowns, and surgical gloves. Powered air purifying respirators (PAPRs) are an acceptable alternative for staff who cannot wear N95 respirators. 5 . CCL readiness and sustainable continuation of operations should be the goal during global pandemics to provide emergency care for at-risk cardiac patients who are the most vulnerable to poor outcomes. Delays in non-emergent procedures may be necessary during major pandemic surges but cannot be deferred indefinitely. 6 . Primary percutaneous coronary intervention (PCI) remains the primary mode of revascularization for patients with STEMI regardless of infection status. A lytic-based strategy is the second-line mode of revascularization at non-PCI capable hospitals or when primary PCI cannot be performed in a timely or safe manner. 7. CCL personnel should be vaccinated against SARS-CoV-2. Patients with cardiovascular disease are at an increased risk of severe disease and death from COVID-19 and should be strongly encouraged to be vaccinated, with consideration for booster doses six months following their second doses of an mRNA vaccine. 8 . Like other respiratory viruses (i.e., influenza), COVID-19 is strongly associated with an increased risk of acute coronary syndromes and myocardial infarction. All patients presenting for emergency cardiac care should be screened for COVID-19 symptoms and considered for screening by polymerase chain reaction (PCR) testing. Patients presenting for non-urgent, elective procedures should undergo symptom screening prior to their procedures. During times of high community transmission and in coordination with hospital leadership, PCR testing should be performed within 72 hours of nonurgent, elective procedures; in patients with positive tests, procedures should be delayed at least ten days when practical and safe. Procedures that cannot be safely delayed should proceed with appropriate infection prevention precautions.

Sterile techniques in the cardiac catheterization laboratory (CCL) have evolved in recent decades, from the days of arterial cutdowns in the 1970s to the current practices of micro-puncture percutaneous vessel entry. (1) Percutaneous valve therapy implantation in the hybrid operating room (OR)/CCL has reinforced the importance of strict sterile techniques and infection control protocols. With over 1 million cardiac catheterization procedures performed annually in the United States (2) , measures in infection control should be standardized to protect both patients and hospital workers.

Recently, the emergent care of patients infected with highly contagious pathogens such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has come to the fore. The resulting 2019 coronavirus disease (COVID-19) pandemic initially posed logistical challenges to limiting the spread of aerosolized pathogens until protocols and procedures were implemented limit infectivity to staff and patients. Ongoing challenges remain as the world faces multiple pandemic waves and novel viral variants. Additionally, the increased risk acute coronary syndromes and cardiogenic shock requiring acute management in the CCL due to multiple mechanisms from COVID-19 (3) At present, the available evidence-based guidelines do not specifically address CCL preparedness and management of patients in the setting of infectious disease pandemic. (1, (4) (5) In this review, we seek to specify best practices in the CCL for the management of infected patients in the pre-procedure, intra-procedure, and postprocedure environments harmonizing available evidence, recommendations from international heart associations, and consensus opinion. (6-10) Epidemiology SARS-CoV-2 is the third highly-pathogenic coronavirus to emerge since 2002, following SARS-CoV-1 and the Middle Eastern respiratory syndrome coronavirus (MERS-CoV). Despite genetic and structural similarities to the original SARS virus, SARS-CoV-2 has a lower case-fatality rate but is markedly more contagious, leading to its dramatic spread around the world and high numbers of total deaths, approaching 700,000 in the United States alone and over 4.7 million deaths worldwide at the time of this writing. (11) (12) (13) Total case-fatality rates for COVID-19 are difficult to measure with accuracy given the large number of undiagnosed or minimally symptomatic cases but may be between 1-2%. Mortality among hospitalized patients in the US has generally decreased over time but ranges between 8-20%, with increased risk of death noted during major surges when hospital resources are more taxed. (14) (15) J o u r n a l P r e -p r o o f

The clinical syndromes produced by COVID-19 are well-known at this point. The majority of affected patients experience mild-to-moderate, self-limited respiratory infections. Patients may be highly contagious and capable of transmitting the virus up to 2 days prior to symptom onset and for 10-21 days afterwards, depending on immune status and disease severity. (16) Severe disease, defined as lower respiratory tract infection with oxygen saturation of less than 94% while breathing ambient air, is more common in older adults, those with obesity, or patients with impaired immunity. The most severely affected patients may progress to the acute respiratory distress syndrome, shock, and multiorgan failure with an elevated hazard of death. (17) A number of therapies have been evaluated for the treatment of COVID-19, with current guidelines recommending supportive care and monoclonal antibodies for mild-tomoderate disease in high-risk individuals. Antiviral drugs (e.g., remdesivir), antithrombotic therapy, glucocorticoids (principally dexamethasone), and immunomodulators such as tocilizumab and baricitinib all play a role in the pharmacologic management of severe disease, depending on illness severity and resource availability. (18) In late 2020, following an extraordinary global research effort, effective vaccines against SARS-CoV-2 were made available. Multiple vaccine platforms have been studied. The current leading vaccines in the US and worldwide are based on either mRNA platforms, using viral mRNA segments that encode for the SARS-CoV-2 spike protein that are then taken up into the host cytosol, transcribed into their protein products, and then induce a host response and resulting protection; or viral vector platforms, most often a nonreplicating adenovirus that has been modified to encode for the same SARS-CoV-2 spike protein. Three vaccines are currently available in the US (mRNA-1273, Moderna; BNT162b2, BioNTech-Pfizer; JNJ-78436735, Janssen/Johnson & Johnson). The efficacy of these vaccines against any infection appears to wane over time, in no small part due to the emergence of the highly-contagious Delta any Omicron variant, but they remain highly effective at preventing hospitalization and death. (19) In September 2021, the Food and Drug Administration authorized booster doses at six months after initial vaccination for high-risk persons, including those 65 years of age or greater, adults with significant medical comorbidities, and those at high risk of occupational exposure (including many health care workers). This was modified in October 2021 to state that boosters may be from any authorized vaccine, not necessarily the specific brand used in the initial vaccination.(20)

In the setting of a pandemic that may last over several years, stockpiles of PPE should be made available for every wave. When CCL teams perform aerosol-generating procedures (AGP) in patients with suspected or confirmed infections, Powered airpurifying respirators (PAPR) should be worn. Per CDC guidance, AGPs in the CCL include (23):

1. Open suction of airway secretions 2. Cardiopulmonary resuscitation 3. Endotracheal intubation and extubation 4. Noninvasive positive pressure ventilation (BIPAP, CPAP) 5. Manual ventilation 6. High-flow oxygen delivery

All HCWs should be vaccinated against SARS-CoV-2 to protect themselves, colleagues, and patients. Many health systems in the United States and elsewhere in the world have policies mandating vaccination against COVID-19 for all HCWs. Such mandates have successfully led to vaccine rates in excess of 90% in affected staff. Despite early concerns regarding mass resignations, rates of staff dismissed due to vaccine non-compliance have been low, often less than 1% of HCWs. (24) Reasons for medical exemptions are rare and should be reviewed with the best available medical evidence, the risks of immunization weighed against the risk of morbidity and mortality to the staff member from COVID-19, and the need to protect vulnerable patients from infection.

Hospital facilities departments and leadership should devise an overarching plan to limit aerosol transmission in procedural areas. Facilities should test the positive pressure ventilation systems of the CCL and verify OR conditions to ensure properly functioning air-handling units with adequate air exchange rate, room differential pressure, relative humidity and air temperature. If possible, hospitals should isolate a single CCL or operating room for patients presumed or confirmed to be infected with COVID-19. Furthermore, modification of ventilation systems should be considered to eliminate the virus from the operating room environment in an expeditious manner. If available, negative pressure ventilation rooms can be designated as the "COVID-19 operating room", thereby providing the ideal protection to healthcare personnel in adjoining operating rooms or corridors. In some instances, departments have been able to convert existing CCLs into negative pressure rooms temporarily. (25) Most importantly, doors of the CCL should remain closed at all times during the procedure. Opening doors could result in loss of positive room pressure and cause viral burden in the air to be dispersed out of the CCL and cross-contaminate adjoining areas, corridors, or even the adjacent operating room. (26, 27) To preserve optimal clean airflow into the CCL or operating room, an OR should have an air exchange rate of greater than or equal to 20 times the room volume in an hour. (28) An air exchange rate lower than that will increase the viral burden in the environment due to stagnant airflow. There are standard calculations for air exchange depending on the pressurization of the operating room. In a positive pressure OR, the following calculation can be made (29) :

Air exchange per hour = Total supply air (m 3 /min) x 60 divided by Room volume (m 3 )

Once adequate air exchanges are confirmed, positive pressurization of the rooms should be confirmed compared to adjoining areas thereby creating the proper barrier between the OR doors to prevent dispersion of airborne viral particles.

Only CCL personnel and healthcare workers involved in the procedure for presumed or confirmed COVID-19 patients should be permitted inside the CCL. As always, the CCL door should remain closed at all times during the procedure. All necessary equipment should be stored within the CCL to avoid opening of the CCL doors to procure supplies. All nonessential personnel such as vendors or visitors should be prohibited from entering the CCL during procedures for presumed or confirmed COVID-19 patients.

With gradual recovery from the peak of the COVID-19 pandemic, CCL have safely resumed elective cardiovascular procedures with continued guiding principles to limit the risk of exposure of CCL healthcare workers to patients with active COVID-19 infection. Central to these principles is the testing of all patients with a single swab 24 to 48 hours prior to their elective procedure. In the event this preliminary test is positive, the patient is instructed to self-isolate and reschedule their elective procedure in 10-14 days with confirmation of a negative test. Successful strategies for CCL recovery are outlined in Figure 3 , Table 2 The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly contagious pathogen leading to its dramatic spread around the world and high numbers of total deaths, approaching 700,000 in the United States and over 4.7 million deaths worldwide. CCL teams are frontline workers and should be provided with N95 respirators, whole face shields or protective eyewear, disposable caps, shoe covers, sterile gowns, and surgical gloves. The CCL needs formal preparedness protocols in the form of consensus evidence-based guidance and guidelines from international heart associations. All CCL personnel should be vaccinated against SARS-CoV-2 along with timely booster vaccinations. Patients with cardiovascular disease are at an increased risk of severe disease and death from COVID-19 and should be strongly encouraged to be vaccinated, with consideration for booster doses six months following their second doses of an mRNA vaccine. Like other respiratory viruses (i.e., influenza), COVID-19 is strongly associated with an increased risk of acute coronary syndromes and myocardial infarction. All patients presenting for emergency cardiac care should be screened for COVID-19 symptoms and considered for screening by polymerase chain reaction (PCR) testing. During times of high community transmission and in coordination with hospital leadership, PCR testing should be performed within 72 hours of non-urgent, elective procedures; in patients with positive tests, procedures should be delayed at least ten days when practical and safe. Procedures that cannot be safely delayed should proceed with appropriate infection prevention precautions.

Further research characterizing the effectiveness of implemented measures during the COVID-19 pandemic so that care givers and medical institutions can understand the logistics of implementing policies. Iterative improvements to minimize transmission of pathogens, particularly aerosolized microorganisms, should be disseminated and routinely reviewed as part of the contingency policies of CCL for future pandemics.

Members of the Catheterization Lab Performance Standards Committee for the Society for Cardiovascular Angiography and Interventions. Infection control guidelines for the cardiac catheterization laboratory: society guidelines revisited

American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation

The Global Effect of the COVID-19 Pandemic on STEMI Care: A Systematic Review and Meta-analysis

Evidence-Based Practices in the Cardiac Catheterization Laboratory: A Scientific Statement From the

SCAI expert consensus update on best practices in the cardiac catheterization laboratory: This statement was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society

American College of Cardiology's Interventional Council and the Society for Cardiovascular Angiography and Interventions. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI

Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP)

European Society for Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic

Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates

Preparedness of the cardiac catheterization laboratory for severe acute respiratory syndrome (SARS) and other epidemics

Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases

Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020

Association Between Caseload Surge and COVID-19

Infectious Diseases Society of America Guidelines on Infection Prevention for Health Care Personnel Caring for Patients with Suspected or Known COVID-19

Severe Covid-19

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions -United States

Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19

Donning and doffing of personal protective equipment (PPE) for angiography during the COVID-19 Crisis

Covid-19: New York's health workers agree to vaccinate as mandate bites

Conversion of operating theatre from positive to negative pressure environment

An evaluation of the environmental factors that impact on operating room air quality and the risk for development of surgical site infections

Airborne particle dispersion to an operating room environment during sliding and hinged door opening

ISO 14644-1, Cleanrooms and associated controlled environments, Classification of air cleanliness. United Kingdom: Institute of Environmental Sciences and Technology

Procedural standards for certified testing of cleanrooms. Adjusting. and Balancing of Environmental Systems

Strategies for Successful Catheterization Laboratory Recovery From the COVID-19 Pandemic

Case Selection During the COVID-19 Pandemic: Who Should Go to the Cardiac Catheterization Laboratory?

Sustainable Resumption of Cardiac Catheterization Laboratory Procedures, and the Importance of Testing, During Endemic COVID-19